Top Story

Higher CD8 T-cell dose from younger donors improves allogeneic HSCT outcomes

Higher CD8 T-cell dose from younger donors improves allogeneic HSCT outcomes
July 2, 2015

A higher graft CD8 dose from younger donors — even if they are not related to the patient — predicted improved survival in patients with hematologic malignancies undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation, according to study results.

Further, a blood test to measure the T lymphocyte count in donors may help identify the best donor match for patients undergoing hematopoietic stem cell transplant (HSCT), the researchers found.

In the Journals

Researchers identify factors that increase mortality risk among patients with MPNs

July 1, 2015
Patients with myeloproliferative neoplasms had a higher mortality rate than the general population, primarily due to hematologic malignancy, infections and vascular…
In the Journals

HSCT improves survival for older patients with multiple myeloma

June 30, 2015
Hematopoietic stem cell transplantation improved OS for elderly patients with multiple myeloma in the real-world setting, according to results of a SEER…
Jai N. Patel, PharmD Pharmacology ConsultPublication Exclusive

Host genetic variants as predictors of chemotherapy-related toxicity in children with ALL: Personalizing the benefit–risk balance

HemOnc Today, June 25, 2015
Jai N. Patel, PharmD
Acute lymphoblastic leukemia is the most common childhood cancer.Intense rounds of chemotherapy — induction, consolidation and maintenance — have resulted in cure rates…
CME
Hematology Oncology Case Consults

The Patient with Chronic Lymphocytic Leukemia

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with chronic lymphocytic leukemia.
More »
Meeting News Coverage Video
AETHERA: Brentuximab vedotin delayed Hodgkin’s lymphoma progression following autologous HSCT

AETHERA: Brentuximab vedotin delayed Hodgkin’s lymphoma progression following autologous HSCT

January 6, 2015
SAN FRANCISCO — John Sweetenham, MD, senior director for clinical affairs and executive medical director of…
More »
Ran Reshef, MD In the Journals

Higher CD8 T-cell dose from younger donors improves allogeneic HSCT outcomes

July 2, 2015
A higher graft CD8 dose from younger donors — even if they are not related to the patient — predicted improved survival in patients with…
In the Journals

Researchers identify factors that increase mortality risk among patients with MPNs

July 1, 2015
Patients with myeloproliferative neoplasms had a higher mortality rate than the general population, primarily due to hematologic malignancy…
In the Journals

HSCT improves survival for older patients with multiple myeloma

June 30, 2015
Hematopoietic stem cell transplantation improved OS for elderly patients with multiple myeloma in the real-world setting, according to results of a…
Jai N. Patel, PharmD Pharmacology ConsultPublication Exclusive

Host genetic variants as predictors of chemotherapy-related toxicity in children with ALL: Personalizing the benefit–risk balance

HemOnc Today, June 25, 2015
Jai N. Patel, PharmD
Acute lymphoblastic leukemia is the most common childhood cancer.Intense rounds of chemotherapy — induction, consolidation and maintenance — have…
Institution Notes

Magazine recognizes ‘extraordinary’ nurse

HemOnc Today, June 25, 2015
Laura Vasquez, RN, CPON, a pediatric oncology nurse at Children’s Hospital Los Angeles, received CURE magazine’s Extraordinary Healer Award for…
FDA News

FDA grants orphan drug designation to ImMucin for multiple myeloma

June 22, 2015
The FDA granted orphan drug designation to ImMucin for the treatment of patients with multiple myeloma, according to a press release from the…
In the Journals

Death rates remain high among cancers caused by cigarette smoking

June 15, 2015
Despite significantly decreasing rates of smoking over the past 50 years, cigarette smoking continues to be the cause of death for various types of…
FDA News

FDA grants orphan drug designation to AG-120 for AML

June 15, 2015
The FDA granted orphan drug designation to AG-120 for the treatment of patients with acute myelogenous leukemia, according to a press release from…
In the Journals

Comorbidities may have greater OS impact in CML than the malignancy

June 15, 2015
Comorbidities had a negative effect on OS but did not impact treatment success in patients with chronic myeloid leukemia, according to study…
Breaking News

Lawmakers introduce Cancer Drug Coverage Parity Act

June 12, 2015
Lawmakers today introduced legislation that would require private health insurance plans with IV chemotherapy benefits to provide equal coverage for…
More Headlines »